BioSpace News Archive

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the fourth quarter and full year ended December 31, 2019.

RTI Surgical Holdings, Inc. announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended, with respect to the proposed sale of RTI’s OEM business to Ardi Bidco Ltd., a Delaware corporation and an entity affiliated with Montagu Private Equity, LLP, expired at 11:59 p.m. Eastern Time on February 28, 2020.

ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), announced that it has agreed to a product supply agreement with Vision Center Network of America, LLC (VCNA).

Kura Oncology, Inc. (Nasdaq: KURA),today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib, for the treatment of adult patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) and nodal peripheral T-cell lymphoma with T follicular helper (TFH) phenotype.

Expands specialty diagnostics portfolio with attractive molecular diagnostics capabilities, including infectious disease testing

Oncolytic virus design and preclinical data to be presented at ESMO TAT, IO Summit Europe, Keystone Symposium and AACR 2020

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced it that it will report its fourth quarter and year-end 2019 financial results on Friday, March 13, 2020.

Itamar Medical Ltd., a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, reported unaudited financial results for the three-month period and year ended December 31, 2019.

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today announced the appointment of Adam Hansard as Chief Commercial Officer.

Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, provided an update today on the clinical advancement of its gene therapy program PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA).